AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01938079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sedative drug regimen
Description: (Standard of Care) Fentanyl or hydromorphone and midazolam infusions will be administered to all patients and titrated at the discretion of the attending physician to maintain the desired level of sedation.
Study NCT00629980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AzaSite®
Description: ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
Study NCT02845323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab in combination with Urelumab
Description: Two cycles of Nivolumab Two cycles of Urelumab
Study NCT02845323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab monotherapy
Description: Two cycles of Nivolumab alone
Study NCT03863886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound catheter (UM-2R/3R, Olympus)
Description: A miniprobe ultrasound catheter (UM-2R/3R, Olympus) will be passed into the colonoscope's accessory channel at the time of colonoscopy to measure the thickness of the different colon wall layers (mucosa, submucosa, muscular propria, and total wall thickness) in the cecum and rectum.
Study NCT02997215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: lidocaine infusion during surgery
Study NCT02997215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: saline infusion at same rate as intervention group during surgery
Study NCT03371836 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clobazam
Description: Clobazam is used as an adjunct medicine for all participants.
Study NCT02735863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: 50 mg or 150mg once daily for 28 days
Study NCT02735863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ABX464 matching placebo
Study NCT01351103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGK974
Study NCT01351103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Study NCT03264586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine-prilocaine cream
Description: 5gm dose of cream applied to the intact surface of the perineum and area covered with an occlusive dressing to facilitate penetration~- EMLA cream was applied, 1 hour before the expected time of birth.
Study NCT03264586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mepivacaine infiltration group
Description: 10 ml of 1% mepivacaine solution was injected slowly when the fetal head was crowned with frequent aspiration to avoid intravascular injection.~* In the mepivacaine group, if an episiotomy was indicated, it was performed after infiltration of perineal tissue with 10 ml of 1% mepivacaine solution.~* The suture procedure was delayed 10 minutes after the injection of the aneathetic
Study NCT03264586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mediolateral episiotomy
Description: Episiotomy repair a loose, continous, non locking suture to close the vaginal mucosa and the muscular layer of the perineum using vicryl Number zero (0).~* At the end of the vaginal mucosal repair care is taken to align the edges of the episiotomy wound~* At the point where perineal skin begins; the suture is then passed beneath the vaginal mucosa, and repair of perineal muscle begins. The deep layer of muscles is closed first, ensuring no dead space one left behind~* The skin was closed with the same continuous suture to approximate the subcutinuous tissue.
Study NCT02475590 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy
Study NCT02475590 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass
Description: Laparoscopic Roux-en-Y gastric bypass
Study NCT02560038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 will be administered as an IV infusion over 10 mg/minute on Days 1 and 8 of each cycle (each cycle is 21 days).
Study NCT02560038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2 will be administered as an IVPB over 3 hours on Day 2 of each cycle (each cycle is 21 days).
Study NCT02560038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 70 mg/m2 will be administered as an IVPB over 2 hours on Day 2 of each cycle (each cycle is 21 days).
Study NCT02111421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 01
Description: Initial dose of dexmedetomidine was 1.0 μg/kg, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points,after the umbilical cord was clapped.The wight used to calculate the dose of dexmedetomidine would be that the total weight of the mother minus the weight of the placenta, amniotic fluid and fetal.
Study NCT02111421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmetomidine 02
Description: Initial dose of dexmedetomidine was 1.0 μg/kg, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points,as soon as the spinal anesthesia
Study NCT02878499 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: polysomnography
Study NCT02257398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944
Description: GSK2140944 is available in dose strength 1000 mg and 1800 mg for single IV dose over 2 hours administration as a pale yellow to greyish yellow cake for reconstitution
Study NCT02257398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 placebo
Description: GSK2140944 placebo is 0.9% sodium chloride available for single IV dose over 2 hours administration.
Study NCT02257398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin is available as pinkish red tablet with dose strength 400 mg for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.
Study NCT02257398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin placebo
Description: Moxifloxacin placebo is available as white, film-coated tablet. containing nonactive material for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.
Study NCT04467736 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gengigel Forte©
Description: Gengigel (hyaluronic acid) will be administered by the patient 3 times per day during 7 days following alveolar ridge preservation
Study NCT03755206 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sustainability strategies
Description: The investigators will work with each site to determine strategies that are relevant locally to help promote sustainability of the suicide prevention program.
Study NCT03473756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib (BAY1163877)
Description: Part A:Rogaratinib will be administered orally until disease progression, unacceptable toxicity or consent withdrawal. The starting dose of 800 mg b.i.d. will be confirmed using a dose selection design.
Study NCT03473756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Part A: A fixed dose of 1200 mg atezolizumab will be administered through intravenous (i.v.) infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity or consent withdrawal.
Study NCT03538418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WAT
Description: The WAT intervention consists of 12 weekly WAT-based exercise sessions and 7 sessions of support for BCTs and technical issues.
Study NCT00628017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 polyunsaturated fatty acids ( EPA+DHA)
Description: Group 1 received omega-3 PUFAs as 3 capsules twice daily (total daily omega-3 fatty acid dosage of 1080 mg of EPA and 720 mg of DHA). Group 2 received three identical placebo capsules twice daily which contained olive oil esters. Identical gelatin capsules were used. Both treatment and placebo capsules were vacuum deodorized and supplemented with tertiary-butyl hydroquinone, 0.2 mg/g, and tocopherols, 2 mg/g, as antioxidants. The source of the omega-3 fatty acids was menhaden fish body oil concentrate.
Study NCT00628017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: omega-3 polyunsaturated fatty acids ( EPA+DHA)
Description: Group 1 received omega-3 PUFAs as 3 capsules twice daily (total daily omega-3 fatty acid dosage of 1080 mg of EPA and 720 mg of DHA). Group 2 received three identical placebo capsules twice daily which contained olive oil esters. Identical gelatin capsules were used. Both treatment and placebo capsules were vacuum deodorized and supplemented with tertiary-butyl hydroquinone, 0.2 mg/g, and tocopherols, 2 mg/g, as antioxidants. The source of the omega-3 fatty acids was menhaden fish body oil concentrate.
Study NCT04050553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT04050553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT01943344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIVASURE CLOSURE DEVICE™
Description: implantation of VIVASURE CLOSURE DEVICE™
Study NCT00635414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg oral
Study NCT00635414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 15 minute intravenous infusion
Study NCT01535040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: memantine hydrochloride
Description: Estimate participation, accrual, adherence, and retention of cancer survivors who smoke and are randomized to receive memantine (10 mg twice daily) or a matching placebo for 12 weeks.
Study NCT01535040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo by mouth through completion of 12 weeks.
Study NCT03919773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG
Description: If you participate in this study there will be 18 scheduled treatment infusions during the 30 week study period. All the study visits and treatment visits will be outpatient visits.~Once you qualify to participate in the study and begin treatment, there will be two 12 week treatment periods separated by a 6 week washout period. The infusion visits will take approximately 3-4 hours each.
Study NCT03919773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albumin
Description: This will be the matching placebo used in the study.
Study NCT00558584 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: protein A immunoadsorption
Description: protein-A immunoadsorption and i.v. IgG substitution
Study NCT00558584 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: pseudo-immunoadsorption
Description: pseudo-immunoadsorption followed by an intravenous infusion without IgG
Study NCT01832636 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alanyl-Glutamine
Description: Alanyl-Glutamine and Glycine doses will be prepared immediately prior to administration by dissolving in formula, milk, or fruit juice. Administration of each dose will be directly observed by a study nurse or health agent.
Study NCT01832636 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alanyl-Glutamine
Description: Alanyl-Glutamine and Glycine doses will be prepared immediately prior to administration by dissolving in formula, milk, or fruit juice. Administration of each dose will be directly observed by a study nurse or health agent.
Study NCT00832663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID
Description: Effect of NSAID ingestion on muscle regeneration
Study NCT00832663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: receive placebo
Study NCT04675190 — intervention group
Intervention type: PROCEDURE
Intervention: Major abdominal Surgery
Description: Any surgery performed under general or regional anesthesia and procedures involving abdominal cavity is considered major abdominal surgery and those who have undergone any major abdominal surgery before 6 months from the date of ultrasound findings confirming the presence or absence of gall stone will be considered exposed.
Study NCT02632162 — intervention group
Intervention type: OTHER
Intervention: screening
Description: Screening for sleep disordered breathing with the ApnoeLink Air device
Study NCT04004936 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EQUIPPED with Active Feedback
Description: Enhancing Quality of Prescribing Practices for Older Adults Discharged from the Emergency Department (EQUIPPED is a multi-component program to reduce the prescribing of potentially inappropriate medications (PIMs) to older adults upon discharge from the Emergency Department (ED). It has three core components: 1) provider education, 2) Electronic Health Record (EHR)-based clinical decision support (CDS) including pharmacy quick order sets to facilitate provider order entry, and 3) provider audit and feedback with peer benchmarking. The active feedback group will receive one-to-one (1:1) in-person academic detailing from a professional colleague that includes in-person audit, feedback, and peer benchmarking and provide on-site expertise.
Study NCT04004936 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EQUIPPED with Passive Feedback
Description: Enhancing Quality of Prescribing Practices for Older Adults Discharged from the Emergency Department (EQUIPPED is a multi-component program to reduce the prescribing of potentially inappropriate medications (PIMs) to older adults upon discharge from the Emergency Department (ED). It has three core components: 1) provider education, 2) Electronic Health Record (EHR)-based clinical decision support (CDS) including pharmacy quick order sets to facilitate provider order entry, and 3) provider audit and feedback with peer benchmarking. The passive feedback group will receive monthly provider feedback via an electronic dashboard with audit, feedback and peer benchmarking.
Study NCT04368559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezafungin for Injection
Description: Intravenous antifungal therapy
Study NCT04368559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Posaconazole
Description: Oral antifungal therapy
Study NCT04368559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Oral antifungal therapy
Study NCT04368559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP/SMX)
Description: Oral antibacterial therapy
Study NCT04368559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Placebo
Description: Normal saline
Study NCT04368559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Microcrystalline cellulose
Study NCT00619333 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: follitropin and lutropin
Description: follitropin and lutropin
Study NCT03207009 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LentiGlobin BB305 Drug Product
Description: LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
Study NCT04038060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drug level feedback
Description: Participants will receive adherence counseling based on tenofovir drug levels
Study NCT04038060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly counseling sessions
Description: Participants will receive monthly counseling on a variety of issues that may be impacting their PrEP adherence
Study NCT02492490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SVFderived MSC transplantations
Description: infusion of autologous SVF derived MSC to the recipients of DCD kidney transplant.~Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD. And the induction therapy of control group will be Basiliximab.
Study NCT02492490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: induction with Basiliximab before kidney transplantation and on POD 4
Study NCT04500522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INH
Description: 3 vaginal tablet of isonicotinic acid hydrazide 900 mg inserted by the patient 12 hours before the scheduled office hysteroscopy.
Study NCT04500522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 vaginal tablet of Placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
Study NCT05376046 — intervention group
Intervention type: BIOLOGICAL
Intervention: Erythrocytic parameters and thrombin generation assay measurement
Description: Erythrocytic parameters and thrombin generation assay measurement
Study NCT04646174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol adapted for smoking cessation
Description: Treatment components are cognitive-behavioral strategies adapted from the Unified Protocol (UP) for the Transdiagnostic Treatment of Emotional Disorders. Behavioral counseling strategies for smoking cessation, drawn from current US Public Health Service guidelines, are incorporated in each treatment module.
Study NCT04646174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: American Lung Association self-management strategies for smoking cessation
Description: Treatment components are self-management strategies provided through printed self-help materials from the American Lung Association. The materials consist of the Freedom from Smoking guide, Relaxation Exercises for Better Breathing, and COPD; Exercise and Daily Activity guide that address evidence-based smoking cessation and self-management strategies to aid in a quit attempt.
Study NCT03462940 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic acid
Description: Tauroursodeoxycholic acid is an ambiphilic bile acid. It is the taurine conjugate form of ursodeoxycholic acid.
Study NCT02583620 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: blood sample
Description: A blood test is realized on the subject
Study NCT01295762 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Immunological analyses
Description: Immunological analyses will be done on blood, bone marrow and tumor samples, at diagnosis, and during the treatment of children diagnosed for neuroblastoma (up to 3 time points). These types of samples are routinely done during conventional neuroblastoma treatment.
Study NCT04290936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemlidy® (Tenofovir Alafenamide; TAF)
Description: Dosage form: Oral Tablets; Dosage: 25mg; Frequency: One tablet with meals, once daily(QD).
Study NCT00698906 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine
Description: 5 different formulations, 2-dose intramuscular injection
Study NCT00698906 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: 3-dose intramuscular injection
Study NCT02398877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stress
Study NCT02520557 — intervention group
Intervention type: OTHER
Intervention: Blood or Saliva
Description: To screen for HLA genotypes that may place patients at high risk of SCAR when they use ESL.
Study NCT02715947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: During The first week: 7.5mg per week, oral; The second and third weeks: 10mg per week, oral; The fourth and fifth weeks: 12.5mg per week,oral; The sixth week:15mg per week, and maintain this dose, oral.
Study NCT01788956 — intervention group
Intervention type: DEVICE
Intervention: Mespere Venous Oximeter
Description: Mespere Venous oximeter provides non-invasive measurement of the oxygenation of the venous blood.
Study NCT01788956 — intervention group
Intervention type: DEVICE
Intervention: Co-Oximeter
Study NCT01325207 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered twice per week for 4 weeks, then once per week for 4 weeks, and then every 2 weeks
Study NCT03338361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: active approach avoidance training and sham visual probe training
Description: patients receive active AAT training and sham VPT training
Study NCT03338361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sham approach avoidance training and active visual probe training
Description: patients receive sham AAT training and active VPT training
Study NCT03338361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: active approach avoidance training and active visual probe training
Description: patients receive active AAT training and active VPT training
Study NCT03338361 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham approach avoidance training and sham visual probe training
Description: patients receive sham AAT training and sham VPT training
Study NCT04330937 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: dietetics
Description: 90 days of consumption
Study NCT04330937 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietetics
Description: 90 days of consumption